Mark Goldin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mark Goldin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alex C. Spyropoulos
Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY 11030, USA
3 shared publications Alex C. Spyropoulos
Northwell Health, New Hyde Park, New York, USA; Feinstein Institute for Medical Research, Northwell, Manhasset, New York, USA; Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA; Elmezzi Graduate School of Molecular Medicine, Manhasset, New York, USA https://twitter.com/AlexSpyropoul
1 shared publicationAriel Goldman
Department of Orthopedics, Northwell Health, Manhasset, New York, USA
1 shared publication- Beverley Jane Hunt
Guy's and St Thomas' NHS Foundation Trust, London, UK
1 shared publication - Daniel Ari Mendelson
University of Rochester
1 shared publication Ermioni Oikonomou
Northwell Health, New Hyde Park, New York, USA; Feinstein Institute for Medical Research, Northwell, Manhasset, New York, USA
1 shared publication
Latest Publications
- Open Access
- 28 August 2026
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 5 (3) , 1-8
Development and implementation of a mathematical model for inpatient warfarin dosing: rationale and methods
Despite a narrow therapeutic range, need for frequent monitoring, and continuous dosing adjustment, vitamin K antagonists like warfarin remain widely prescribed worldwide owing to superiority over newer anticoagulants in key patient populations and low cost. Several models exist to guide warfarin dosing in stable outpatients, but none validated for inpatient warfarin dosing. Instead, clinicians use blanket pre-specified warfarin initiation strategies, and adjust the dose based on clinical gestalt. There is a need for warfarin dosing guidance during the inpatient period to improve time to achieve the therapeutic effect, potentially decrease adverse events related to over- or under-anticoagulation, and reduce hospitalization times. Warfarin response is characterized by inter-individual and inter-temporal variability. At the same time, modern electronic health record infrastructure has made relevant data easily accessible. A simplified pharmacokinetic/pharmacodynamic (PK/PD) model for inpatient warfarin dosing has been previously described, but no implementation has been disseminated. This methods paper is intended to introduce a stepwise derivation and an open-source implementation of this previously described simplified PK/PD model designed for warfarin dosing in the inpatient setting that can be used for subsequent large-scale validation. The model has the potential, after extensive validation and extension, to serve as the core of a clinical decision support system that can accurately provide dosing recommendations to clinicians.
- 28 August 2026
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 5 (3) , 1-8
Open AccessDevelopment and implementation of a mathematical model for inpatient warfarin dosing: rationale and methods
Despite a narrow therapeutic range, need for frequent monitoring, and continuous dosing adjustment, vitamin K antagonists like warfarin remain widely prescribed worldwide owing to superiority over newer anticoagulants in key patient populations and low cost. Several models exist to guide warfarin dosing in stable outpatients, but none validated for inpatient warfarin dosing. Instead, clinicians use blanket pre-specified warfarin initiation strategies, and adjust the dose based on clinical gestalt. There is a need for warfarin dosing guidance during the inpatient period to improve time to achieve the therapeutic effect, potentially decrease adverse events related to over- or under-anticoagulation, and reduce hospitalization times. Warfarin response is characterized by inter-individual and inter-temporal variability. At the same time, modern electronic health record infrastructure has made relevant data easily accessible. A simplified pharmacokinetic/pharmacodynamic (PK/PD) model for inpatient warfarin dosing has been previously described, but no implementation has been disseminated. This methods paper is intended to introduce a stepwise derivation and an open-source implementation of this previously described simplified PK/PD model designed for warfarin dosing in the inpatient setting that can be used for subsequent large-scale validation. The model has the potential, after extensive validation and extension, to serve as the core of a clinical decision support system that can accurately provide dosing recommendations to clinicians.
- 3 February 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (2) , 368-371
Bleeding risk prediction models in varied clinical scenarios
- 3 February 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (2) , 368-371
Bleeding risk prediction models in varied clinical scenarios
- 27 December 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (10) , 2226-2236
Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH
- 27 December 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (10) , 2226-2236
Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH
- 21 February 2022
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (08) , 1279-1287
State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism
Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low-flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high-flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and comorbidities predisposing individuals with VTE to ATE, and vice versa, and have bolstered the strategy of dual-pathway inhibition (DPI)—the combination of low-dose anticoagulants with antiplatelet agents—to reduce thrombotic outcomes on both sides of the vasculature. Randomized clinical trials have evaluated the efficacy and safety of such regimens—mostly rivaroxaban and aspirin—in high-risk groups of patients, including those with recent acute or chronic coronary syndrome, as well as those with peripheral artery disease with or without revascularization. Studies of extended VTE prophylaxis in acutely ill medical patients have also contributed to the evidence evaluating DPI. The totality of available data supports the concept that DPI can reduce major and fatal thromboembolic outcomes, including stroke, myocardial infarction, VTE, and cardiovascular death in key patient cohorts, with acceptable risk of bleeding. Further data are needed to refine which patients derive the best net clinical benefit from such an approach. At the same time, other novel agents such as contact pathway inhibitors that reduce thrombin generation without affecting hemostasis—and thus maximize safety—should be assessed in appropriate populations.
- 21 February 2022
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (08) , 1279-1287
State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism
Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low-flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high-flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and comorbidities predisposing individuals with VTE to ATE, and vice versa, and have bolstered the strategy of dual-pathway inhibition (DPI)—the combination of low-dose anticoagulants with antiplatelet agents—to reduce thrombotic outcomes on both sides of the vasculature. Randomized clinical trials have evaluated the efficacy and safety of such regimens—mostly rivaroxaban and aspirin—in high-risk groups of patients, including those with recent acute or chronic coronary syndrome, as well as those with peripheral artery disease with or without revascularization. Studies of extended VTE prophylaxis in acutely ill medical patients have also contributed to the evidence evaluating DPI. The totality of available data supports the concept that DPI can reduce major and fatal thromboembolic outcomes, including stroke, myocardial infarction, VTE, and cardiovascular death in key patient cohorts, with acceptable risk of bleeding. Further data are needed to refine which patients derive the best net clinical benefit from such an approach. At the same time, other novel agents such as contact pathway inhibitors that reduce thrombin generation without affecting hemostasis—and thus maximize safety—should be assessed in appropriate populations.
- 11 May 2020
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 68 (8) , 1706-1713
Implementation of Hip Fracture Co‐Management Program ( AGS CoCare: Ortho® ) in a Large Health System
OBJECTIVES: Acute hip fracture is common and leads to significant morbidity and mortality. Co‐management programs, such as American Geriatric Society (AGS) CoCare: Ortho ® , that optimize perioperative care of older adults, have demonstrated improved outcomes. Yet there is substantial variation in hip fracture care nationally. Our objective was to describe the implementation of AGS CoCare: Ortho ® across a large integrated health system. DESIGN: Program implementation of four phases. SETTING: Large integrated health system. PARTICIPANTS: One tertiary and three community hospitals. MEASUREMENTS: The first two phases were communication and system‐level planning. The communication phase consisted of getting health system leadership buy‐in, creating an interdisciplinary steering committee, and building a business model. The planning phase consisted of choosing process and outcome measures, ensuring accurate and timely data collection, and creating standardized order sets and physician documentation. RESULTS: The second two phases were hospital‐level planning and implementation. The planning phase consisted of identifying sites and developing the co‐management structure. The implementation phase consisted of identifying and engaging frontline staff, rolling out the program, optimizing workflow, and educating providers. CONCLUSION: The program was implemented at four diverse sites. Major lessons learned included the need for an engaged steering committee to oversee the program; the importance of standardizing order sets and documentation; the utilization of hospitalists as co‐managers; the benefit of developing and actively using a data dashboard; the challenge of ensuring wide uptake of education modules; and the need to take proactive steps to improve multidisciplinary communication. J Am Geriatr Soc 68:1706‐1713, 2020.
- 11 May 2020
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 68 (8) , 1706-1713
Implementation of Hip Fracture Co‐Management Program ( AGS CoCare: Ortho® ) in a Large Health System
OBJECTIVES: Acute hip fracture is common and leads to significant morbidity and mortality. Co‐management programs, such as American Geriatric Society (AGS) CoCare: Ortho ® , that optimize perioperative care of older adults, have demonstrated improved outcomes. Yet there is substantial variation in hip fracture care nationally. Our objective was to describe the implementation of AGS CoCare: Ortho ® across a large integrated health system. DESIGN: Program implementation of four phases. SETTING: Large integrated health system. PARTICIPANTS: One tertiary and three community hospitals. MEASUREMENTS: The first two phases were communication and system‐level planning. The communication phase consisted of getting health system leadership buy‐in, creating an interdisciplinary steering committee, and building a business model. The planning phase consisted of choosing process and outcome measures, ensuring accurate and timely data collection, and creating standardized order sets and physician documentation. RESULTS: The second two phases were hospital‐level planning and implementation. The planning phase consisted of identifying sites and developing the co‐management structure. The implementation phase consisted of identifying and engaging frontline staff, rolling out the program, optimizing workflow, and educating providers. CONCLUSION: The program was implemented at four diverse sites. Major lessons learned included the need for an engaged steering committee to oversee the program; the importance of standardizing order sets and documentation; the utilization of hospitalists as co‐managers; the benefit of developing and actively using a data dashboard; the challenge of ensuring wide uptake of education modules; and the need to take proactive steps to improve multidisciplinary communication. J Am Geriatr Soc 68:1706‐1713, 2020.